文献速递青光眼

小梁切除术中丝裂霉素C注射与海绵应用的比较:美国眼科学会报告

Mitomycin C Application during Trabeculectomy-Injection versus Sponge: A Report by the American Academy of Ophthalmology.
PubMed 文献 · Ophthalmology · 2026-10-07

该报告基于PubMed检索(截至2026年5月)的11项研究,评估小梁切除术中丝裂霉素C(MMC)经注射(MMC-I)与海绵(MMC-S)应用的疗效与安全性。结果显示,两种方式在手术成功率(降低眼压和减少用药负担)及安全性方面相似,但MMC-I在滤过泡形态上可能更具优势。

要点

  • MMC-I与MMC-S在小梁切除术中的手术成功率和安全性相似。
  • MMC-I组滤过泡形态更优(弥漫、低平、血管少)。
  • MMC-I组5-氟尿嘧啶注射次数更少,MMC-S组再手术更多。

核心结论

  • I级和II级证据支持小梁切除术中MMC经注射或海绵应用均可,两者手术成功率和安全性相似。
  • MMC-I可能在滤过泡形态上优于MMC-S。

研究设计与样本

  • 美国眼科学会报告,通过PubMed检索(截至2026年5月)获得135篇文章,最终纳入11项符合标准的研究。
  • 纳入研究中6项为I级证据,2项为II级证据,3项为III级证据。

主要发现

  • MMC-I组完全成功率范围为40.3%至90.9%,MMC-S组为17.7%至86.5%。
  • MMC-I组眼压较基线变化范围为2.8 mmHg(17%)至19.4 mmHg(58%),MMC-S组为5.8 mmHg(31%)至18.0 mmHg(59%)。
  • 两组在滤过泡渗漏、低眼压、脉络膜渗出或脉络膜出血等并发症率上无显著差异。
  • 两项研究报告MMC-I组5-氟尿嘧啶注射次数显著更少,一项报告MMC-S组青光眼再手术更多。

关键数值与推荐

  • MMC-I使用的药物浓度范围(0.05-0.4 mg/mL)比MMC-S(0.1-0.4 mg/mL)更广。
  • 多数研究纳入原发性开角型青光眼患者。

临床怎么用

  • 小梁切除术中可选择MMC注射或海绵应用,两者成功率与安全性相似。
  • 若关注滤过泡形态或减少术后5-氟尿嘧啶注射,可考虑MMC注射。

局限性

  • 成功率范围宽可能源于成功定义、随访时间和患者人群的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the recently published literature on the efficacy and safety outcomes of delivering mitomycin C (MMC) by either sub-Tenon's/subconjunctival injection (MMC-I) or by sponge (MMC-S) during trabeculectomy surgery. METHODS: A literature search was last conducted in the PubMed database in May 2026 and yielded 135 articles. Eighteen full-text articles were reviewed, and 11 met all inclusion criteria for this assessment and were assigned a level of evidence rating by the panel methodologist. RESULTS: Six studies were rated level I, 2 were rated level II, and 3 were rated level III. The racial and ethnic backgrounds of study participants represented a diverse mix, and in many studies, a variety of glaucoma diagnoses were included, the majority of which were primary open-angle glaucoma. The MMC-I technique was reported to have used a wider range of drug concentrations (0.05-0.4 mg/mL) than MMC-S (0.1-0.4 mg/mL). The complete success rate of intraocular pressure (IOP) control ranged from 40.3% to 90.9% in the MMC-I group compared with 17.7% to 86.5% in the MMC-S group. The wide range of success rates may be a result of differences in definitions of success, follow-up time, and patient populations. Change in IOP from baseline ranged from 2.8 mmHg (17%) to 19.4 mmHg (58%) in the MMC-I group compared with 5.8 mmHg (31%) to 18.0 mmHg (59%) in the MMC-S group. No significant differences in complications, such as rates of bleb leak, hypotony, choroidal effusion, or choroidal hemorrhage, were reported. Two studies reported significantly fewer 5-fluorouracil injections in the MMC-I group, and 1 reported more glaucoma surgery reoperations in the MMC-S group. Several studies reported a more favorable bleb morphology that was diffuse, lower profile, and less vascular in the MMC-I group than in the MMC-S group. CONCLUSIONS: Although MMC-I may offer some advantages over MMC-S trabeculectomy with respect to bleb morphology, level I and II evidence supports the application of MMC using either injection or sponges during trabeculectomy. Both applications result in similar rates of surgical success (a lower IOP and a reduction in medication burden) and have a similar safety profile. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Lim MC, Solá-Del Valle D, Rosdahl JA, et al. Mitomycin C Application during Trabeculectomy-Injection versus Sponge: A Report by the American Academy of Ophthalmology. Ophthalmology. 2026. PMID: 42841846. doi:10.1016/j.ophtha.2026.07.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。